Head-to-head · Cost-Efficiency Index
Invigor Medical vs NP2GO
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Invigor Medical
Value shoppers who want competitive pricing on both molecules plus a wider wellness/hormone program on one account.
Visit Invigor MedicalNP2GO
Shoppers inside its 40 served states who want both molecules disclosed and will vet the pharmacy themselves.
Visit NP2GOThe verdict
Invigor Medical takes it, leading the Cost-Efficiency Index 88 to 79. Solid mid-market cost on both molecules from an established operator — good value if you also want a broader metabolic and hormone catalog. NP2GO still earns a C — Shoppers inside its 40 served states who want both molecules disclosed and will vet the pharmacy themselves.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the board). See how it stacks up: CoreAge Rx vs Invigor Medical.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Invigor Medical | NP2GO |
|---|---|---|
| Cost-Efficiency Index | 88/100 | 79/100 |
| Semaglutide / mo | $199/mo | $150/mo |
| Tirzepatide / mo | $339/mo | $250/mo |
| Semaglutide / yr (modeled) | $2,388 | $1,800 |
| Tirzepatide / yr (modeled) | $4,068 | $3,000 |
| Coverage | Not disclosed | AK, AZ, AR, CA, CO, CT, DE, DC, FL, HI, ID, IL, IA, KS, KY, ME, MD, MA, MI, MN, MT, NE, NV, NH, NJ, NM, NY, ND, OK, OR, PA, RI, SD, TX, UT, VT, VA, WA, WV, WY |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank on the board | #4 | #24 |
Invigor Medical
88/100Where the value is
- Competitive mid-market pricing on both semaglutide and tirzepatide
- Long-running operator with a broad catalog that can consolidate spend
- Both molecules published up front for easy cost modeling
The tradeoffs
- Does not publish an explicit states-served list, so access is a variable in the model
- Compounded only
NP2GO
79/100Where the value is
- Both molecules disclosed — $150 semaglutide / $250 tirzepatide — for straightforward cost modeling
- Broad 40-state footprint — wider than most non-nationwide operators
- Flat, predictable pricing
The tradeoffs
- 40 states, not all 50 — a coverage gamble that dents its access score
- Not LegitScript-certified — oversight harder to verify
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.